<?xml version="1.0"?> <rss version="2.0" xmlns:prism="http://purl.org/rss/1.0/modules/prism/"> <channel> <title>JAMA Current Issue</title> <link>https://jamanetwork.com/journals/jama</link> <description> </description> <language>en-us</language> <pubDate>Tue, 19 Nov 2024 00:00:00 GMT</pubDate> <lastBuildDate>Tue, 19 Nov 2024 11:43:24 GMT</lastBuildDate> <generator>Silverchair</generator> <managingEditor>jamams@jamanetwork.org</managingEditor> <webMaster>support@jamanetwork.com</webMaster> <item> <title>JAMA</title> <link>https://jamanetwork.com/journals/jama/fullarticle/2826235</link> <pubDate>Tue, 19 Nov 2024 00:00:00 GMT</pubDate> <description /> <prism:volume xmlns:prism="prism">332</prism:volume> <prism:number xmlns:prism="prism">19</prism:number> <prism:startingPage xmlns:prism="prism">1595</prism:startingPage> <prism:endingPage xmlns:prism="prism">1596</prism:endingPage> <prism:doi xmlns:prism="prism">10.1001/jama.2023.18457</prism:doi> <guid>2826235</guid> </item> <item> <title>HHS Will Provide Free US-Made COVID-19 Tests to Households</title> <link>https://jamanetwork.com/journals/jama/fullarticle/2825532</link> <pubDate>Tue, 19 Nov 2024 00:00:00 GMT</pubDate> <description>The Administration for Strategic Preparedness and Response, an agency within the US Department of Health and Human Services, has announced the reopening of COVIDTests.gov to deliver free COVID-19 tests to households. The agency’s investment of $600 million to 12 domestic test manufacturers will supply 200 million home tests.</description> <prism:volume xmlns:prism="prism">332</prism:volume> <prism:number xmlns:prism="prism">19</prism:number> <prism:startingPage xmlns:prism="prism">1602</prism:startingPage> <prism:endingPage xmlns:prism="prism">1602</prism:endingPage> <prism:doi xmlns:prism="prism">10.1001/jama.2024.21819</prism:doi> <guid>2825532</guid> </item> <item> <title>Study Cautions Against Mouth Taping for Patients With Sleep Apnea</title> <link>https://jamanetwork.com/journals/jama/fullarticle/2825531</link> <pubDate>Tue, 19 Nov 2024 00:00:00 GMT</pubDate> <description>Mouth taping is a sleep technique that has been promoted widely across social media. Although mouth breathing during sleep is associated with severity of obstructive sleep apnea (OSA), research recently published in JAMA Otolaryngology–Head &amp;amp; Neck Surgery suggests that it may be important to maintain airflow in some patients with nasal obstruction.</description> <prism:volume xmlns:prism="prism">332</prism:volume> <prism:number xmlns:prism="prism">19</prism:number> <prism:startingPage xmlns:prism="prism">1602</prism:startingPage> <prism:endingPage xmlns:prism="prism">1602</prism:endingPage> <prism:doi xmlns:prism="prism">10.1001/jama.2024.21820</prism:doi> <guid>2825531</guid> </item> <item> <title>AAP Issues First Opioid Prescribing Guideline for Children</title> <link>https://jamanetwork.com/journals/jama/fullarticle/2825530</link> <pubDate>Tue, 19 Nov 2024 00:00:00 GMT</pubDate> <description>The American Academy of Pediatrics (AAP) released its first clinical guidance on prescribing opioids for outpatient acute pain management to youth. Although it cautions against the dangers of rising opioid use disorder among children and teens, it also notes that a decrease in opioid prescription rates may leave some youth with pain that is not adequately treated.</description> <prism:volume xmlns:prism="prism">332</prism:volume> <prism:number xmlns:prism="prism">19</prism:number> <prism:startingPage xmlns:prism="prism">1602</prism:startingPage> <prism:endingPage xmlns:prism="prism">1602</prism:endingPage> <prism:doi xmlns:prism="prism">10.1001/jama.2024.21821</prism:doi> <guid>2825530</guid> </item> <item> <title>Study: MMR Vaccine Protection Wanes Slightly Over Time</title> <link>https://jamanetwork.com/journals/jama/fullarticle/2825529</link> <pubDate>Tue, 19 Nov 2024 00:00:00 GMT</pubDate> <description>Although most measles cases in England occur among unvaccinated individuals, the proportion of cases among those who were fully vaccinated with 2 doses of the measles, mumps, and rubella (MMR) vaccine increased between 2010 and 2019.</description> <prism:volume xmlns:prism="prism">332</prism:volume> <prism:number xmlns:prism="prism">19</prism:number> <prism:startingPage xmlns:prism="prism">1602</prism:startingPage> <prism:endingPage xmlns:prism="prism">1602</prism:endingPage> <prism:doi xmlns:prism="prism">10.1001/jama.2024.21822</prism:doi> <guid>2825529</guid> </item> <item> <title>FDA Approves Novel Schizophrenia Drug</title> <link>https://jamanetwork.com/journals/jama/fullarticle/2825528</link> <pubDate>Tue, 19 Nov 2024 00:00:00 GMT</pubDate> <description>The US Food and Drug Administration (FDA) recently approved a new treatment for schizophrenia that relies on a novel mechanism of action. Oral xanomeline and trospium chloride, marketed as Cobenfy, is the first antipsychotic drug authorized to treat the disease via cholinergic receptors instead of dopamine receptors, which has historically been the therapeutic pathway.</description> <prism:volume xmlns:prism="prism">332</prism:volume> <prism:number xmlns:prism="prism">19</prism:number> <prism:startingPage xmlns:prism="prism">1603</prism:startingPage> <prism:endingPage xmlns:prism="prism">1603</prism:endingPage> <prism:doi xmlns:prism="prism">10.1001/jama.2024.21823</prism:doi> <guid>2825528</guid> </item> <item> <title>Study: Redlining Linked With Shorter Life Expectancy</title> <link>https://jamanetwork.com/journals/jama/fullarticle/2825527</link> <pubDate>Tue, 19 Nov 2024 00:00:00 GMT</pubDate> <description>Adding to decades of evidence on the negative effects of the historical discriminatory practice called redlining, a new study finds that those who lived in redlined neighborhoods in 1940 had a lower life expectancy than those who did not.</description> <prism:volume xmlns:prism="prism">332</prism:volume> <prism:number xmlns:prism="prism">19</prism:number> <prism:startingPage xmlns:prism="prism">1603</prism:startingPage> <prism:endingPage xmlns:prism="prism">1603</prism:endingPage> <prism:doi xmlns:prism="prism">10.1001/jama.2024.21824</prism:doi> <guid>2825527</guid> </item> <item> <title>Bright Light Therapy Not Effective for Major Depressive Disorder</title> <link>https://jamanetwork.com/journals/jama/fullarticle/2825526</link> <pubDate>Tue, 19 Nov 2024 00:00:00 GMT</pubDate> <description>Bright light therapy is often used to treat seasonal depressive disorder, but the results of a recent trial in JAMA Psychiatry suggest that its benefits may not extend to treatment of depressive disorders in hospitalized adolescents.</description> <prism:volume xmlns:prism="prism">332</prism:volume> <prism:number xmlns:prism="prism">19</prism:number> <prism:startingPage xmlns:prism="prism">1603</prism:startingPage> <prism:endingPage xmlns:prism="prism">1603</prism:endingPage> <prism:doi xmlns:prism="prism">10.1001/jama.2024.21825</prism:doi> <guid>2825526</guid> </item> <item> <title>Few Patients Receive Testing After Abnormal Urine Protein Results</title> <link>https://jamanetwork.com/journals/jama/fullarticle/2825525</link> <pubDate>Tue, 19 Nov 2024 00:00:00 GMT</pubDate> <description>Too few patients with abnormal urine protein dipstick test results receive the recommended follow-up with albumin to creatinine ratio (ACR) testing to assess albuminuria, a risk factor for chronic kidney disease, according to new research published in the Annals of Internal Medicine.</description> <prism:volume xmlns:prism="prism">332</prism:volume> <prism:number xmlns:prism="prism">19</prism:number> <prism:startingPage xmlns:prism="prism">1603</prism:startingPage> <prism:endingPage xmlns:prism="prism">1603</prism:endingPage> <prism:doi xmlns:prism="prism">10.1001/jama.2024.21826</prism:doi> <guid>2825525</guid> </item> <item> <title>Myopia Cases Are Rising at Alarming Rates in Children, Teens</title> <link>https://jamanetwork.com/journals/jama/fullarticle/2825524</link> <pubDate>Tue, 19 Nov 2024 00:00:00 GMT</pubDate> <description>This Medical News article discusses new research on global trends in nearsightedness, possible ways to prevent and treat it, and calls to classify it as a disease.</description> <prism:volume xmlns:prism="prism">332</prism:volume> <prism:number xmlns:prism="prism">19</prism:number> <prism:startingPage xmlns:prism="prism">1599</prism:startingPage> <prism:endingPage xmlns:prism="prism">1601</prism:endingPage> <prism:doi xmlns:prism="prism">10.1001/jama.2024.21043</prism:doi> <guid>2825524</guid> </item> <item> <title>Why Are Pertussis Cases On the Rise?</title> <link>https://jamanetwork.com/journals/jama/fullarticle/2825523</link> <pubDate>Tue, 19 Nov 2024 00:00:00 GMT</pubDate> <description>This Medical News article discusses the reasons behind the resurgence of pertussis in the US and elsewhere this year.</description> <prism:volume xmlns:prism="prism">332</prism:volume> <prism:number xmlns:prism="prism">19</prism:number> <prism:startingPage xmlns:prism="prism">1597</prism:startingPage> <prism:endingPage xmlns:prism="prism">1598</prism:endingPage> <prism:doi xmlns:prism="prism">10.1001/jama.2024.22533</prism:doi> <guid>2825523</guid> </item> <item> <title>Audio Highlights October 19-25, 2024 </title> <link>https://jamanetwork.com/journals/jama/fullarticle/2825493</link> <pubDate>Tue, 19 Nov 2024 00:00:00 GMT</pubDate> <description>Listen to the JAMA Editor’s Summary for an overview and discussion of the important articles appearing in JAMA.</description> <prism:volume xmlns:prism="prism">332</prism:volume> <prism:number xmlns:prism="prism">19</prism:number> <prism:startingPage xmlns:prism="prism">e2318437</prism:startingPage> <prism:doi xmlns:prism="prism">10.1001/jama.2023.18437</prism:doi> <guid>2825493</guid> </item> <item> <title>Revisions to List of Nonauthor Collaborators</title> <link>https://jamanetwork.com/journals/jama/fullarticle/2825332</link> <pubDate>Tue, 19 Nov 2024 00:00:00 GMT</pubDate> <description>The Original Investigation titled “Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials,” published on July 22, 2024, has been updated to fix the affiliation for Nobuo Aoyama and add the names of investigators (Federico Arguelles Arias, Toshiyuki Endo, Jill Gaidos, Jee Hyun Kim, Albert Pirmagomedov, and Nikolaos Viazis) missing from the original version of Supplement 3. This article was corrected online.</description> <prism:volume xmlns:prism="prism">332</prism:volume> <prism:number xmlns:prism="prism">19</prism:number> <prism:startingPage xmlns:prism="prism">1676</prism:startingPage> <prism:endingPage xmlns:prism="prism">1676</prism:endingPage> <prism:doi xmlns:prism="prism">10.1001/jama.2024.21794</prism:doi> <guid>2825332</guid> </item> <item> <title>Prevention, Diagnosis, and Treatment of Acute Altitude Illness</title> <link>https://jamanetwork.com/journals/jama/fullarticle/2825331</link> <pubDate>Tue, 19 Nov 2024 00:00:00 GMT</pubDate> <description>This JAMA Clinical Guidelines Synopsis summarizes the Wilderness Medical Society’s 2024 recommendations on prevention, diagnosis, and treatment of acute altitude illness.</description> <prism:volume xmlns:prism="prism">332</prism:volume> <prism:number xmlns:prism="prism">19</prism:number> <prism:startingPage xmlns:prism="prism">1665</prism:startingPage> <prism:endingPage xmlns:prism="prism">1666</prism:endingPage> <prism:doi xmlns:prism="prism">10.1001/jama.2024.19562</prism:doi> <guid>2825331</guid> </item> <item> <title>The Surgery of the Heart</title> <link>https://jamanetwork.com/journals/jama/fullarticle/2825330</link> <pubDate>Tue, 19 Nov 2024 00:00:00 GMT</pubDate> <description>Some of the most dramatic chapters in the history of medicine deal with the development of surgery. “A good surgeon must have an eagle’s eye, a lion’s heart, a lady’s hand.” Thus runs the old English proverb, formulated in the days before anesthetics banished pain and antiseptics averted the horrors of wound infection. Today no large part of the body is destined to remain free from surgical approach. The abdomen, thorax and cranium have already been invaded by the trained surgeon with eminent success in the relief of a variety of maladies. Blood vessel and nerve surgery have been developed to a high degree of skill.…This progress has called not only for great resourcefulness of hand and mind but also for personal courage. The pioneer into uncharted places usually proceeds at his own peril only; he pays the penalty for failure with his own person. The surgical pioneer, however, literally takes the lives of others in his hand, and that is a sobering responsibility. Daring, under such circumstances, must be fortified with wisdom and stamina.</description> <prism:volume xmlns:prism="prism">332</prism:volume> <prism:number xmlns:prism="prism">19</prism:number> <prism:startingPage xmlns:prism="prism">1678</prism:startingPage> <prism:endingPage xmlns:prism="prism">1678</prism:endingPage> <prism:doi xmlns:prism="prism">10.1001/jama.2023.18459</prism:doi> <guid>2825330</guid> </item> <item> <title>Fecal Immunochemical Test vs Stool RNA Testing for Colorectal Cancer Screening</title> <link>https://jamanetwork.com/journals/jama/fullarticle/2825329</link> <pubDate>Tue, 19 Nov 2024 00:00:00 GMT</pubDate> <description>To the Editor We read with interest the recent study that compared the fecal immunochemical test (FIT) positivity threshold vs multitarget stool RNA (mt-sRNA) testing for colorectal cancer screening. However, we have concerns regarding the study methodology and the capability of FIT to fully replace the mt-sRNA panel.</description> <prism:volume xmlns:prism="prism">332</prism:volume> <prism:number xmlns:prism="prism">19</prism:number> <prism:startingPage xmlns:prism="prism">1675</prism:startingPage> <prism:endingPage xmlns:prism="prism">1675</prism:endingPage> <prism:doi xmlns:prism="prism">10.1001/jama.2024.18535</prism:doi> <guid>2825329</guid> </item> <item> <title>Fecal Immunochemical Test vs Stool RNA Testing for Colorectal Cancer Screening—Reply</title> <link>https://jamanetwork.com/journals/jama/fullarticle/2825328</link> <pubDate>Tue, 19 Nov 2024 00:00:00 GMT</pubDate> <description>In Reply Our study adjusted the FIT cutoff to yield the same overall positivity rate as reported for the mt-sRNA test (17%) to enhance comparability of diagnostic performance of both tests. Below we address each of the 3 points made by Drs Yang and Ma.</description> <prism:volume xmlns:prism="prism">332</prism:volume> <prism:number xmlns:prism="prism">19</prism:number> <prism:startingPage xmlns:prism="prism">1676</prism:startingPage> <prism:endingPage xmlns:prism="prism">1676</prism:endingPage> <prism:doi xmlns:prism="prism">10.1001/jama.2024.18538</prism:doi> <guid>2825328</guid> </item> <item> <title>Patient Information: Allergic Rhinitis</title> <link>https://jamanetwork.com/journals/jama/fullarticle/2825326</link> <pubDate>Tue, 19 Nov 2024 00:00:00 GMT</pubDate> <description>This JAMA Patient Page describes allergic rhinitis and its risk factors, diagnosis, and treatment.</description> <prism:volume xmlns:prism="prism">332</prism:volume> <prism:number xmlns:prism="prism">19</prism:number> <prism:startingPage xmlns:prism="prism">1682</prism:startingPage> <prism:endingPage xmlns:prism="prism">1682</prism:endingPage> <prism:doi xmlns:prism="prism">10.1001/jama.2024.14237</prism:doi> <guid>2825326</guid> </item> <item> <title>I Spy</title> <link>https://jamanetwork.com/journals/jama/fullarticle/2825325</link> <pubDate>Tue, 19 Nov 2024 00:00:00 GMT</pubDate> <description>In this narrative medicine essay, a pediatric oncology fellow who weaves storytelling into her practice to help patients process their illness describes how a young boy’s mother captures his story through photography.</description> <prism:volume xmlns:prism="prism">332</prism:volume> <prism:number xmlns:prism="prism">19</prism:number> <prism:startingPage xmlns:prism="prism">1613</prism:startingPage> <prism:endingPage xmlns:prism="prism">1614</prism:endingPage> <prism:doi xmlns:prism="prism">10.1001/jama.2024.19568</prism:doi> <guid>2825325</guid> </item> <item> <title>Prevention of Anal Cancer in High-Risk Individuals</title> <link>https://jamanetwork.com/journals/jama/fullarticle/2825313</link> <pubDate>Tue, 19 Nov 2024 00:00:00 GMT</pubDate> <description>This JAMA Insights examines the treatment and rising prevalence of anal cancer in the US in high-risk groups, including people with HIV and immunosuppression associated with solid organ transplant.</description> <prism:volume xmlns:prism="prism">332</prism:volume> <prism:number xmlns:prism="prism">19</prism:number> <prism:startingPage xmlns:prism="prism">1663</prism:startingPage> <prism:endingPage xmlns:prism="prism">1664</prism:endingPage> <prism:doi xmlns:prism="prism">10.1001/jama.2024.17870</prism:doi> <guid>2825313</guid> </item> <item> <title>GLP-1RA and SGLT2 Inhibitor Prescribing in People With Diabetes</title> <link>https://jamanetwork.com/journals/jama/fullarticle/2825312</link> <pubDate>Tue, 19 Nov 2024 00:00:00 GMT</pubDate> <description>This pooled cross-sectional study explores prescribing rates for glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors among US patients with type 1 diabetes.</description> <prism:volume xmlns:prism="prism">332</prism:volume> <prism:number xmlns:prism="prism">19</prism:number> <prism:startingPage xmlns:prism="prism">1667</prism:startingPage> <prism:endingPage xmlns:prism="prism">1669</prism:endingPage> <prism:doi xmlns:prism="prism">10.1001/jama.2024.18581</prism:doi> <guid>2825312</guid> </item> <item> <title>The Diagnosis</title> <link>https://jamanetwork.com/journals/jama/fullarticle/2825310</link> <pubDate>Tue, 19 Nov 2024 00:00:00 GMT</pubDate> <description>When you hear the cancer doctor we just met read the biopsy results from your PET scan, the issues leading up to this moment, directly off an Epic chart with precision, wonder: then </description> <prism:volume xmlns:prism="prism">332</prism:volume> <prism:number xmlns:prism="prism">19</prism:number> <prism:startingPage xmlns:prism="prism">1677</prism:startingPage> <prism:endingPage xmlns:prism="prism">1677</prism:endingPage> <prism:doi xmlns:prism="prism">10.1001/jama.2024.14691</prism:doi> <guid>2825310</guid> </item> <item> <title>Meeting the Unmet Needs in Rare Cancer</title> <link>https://jamanetwork.com/journals/jama/fullarticle/2825271</link> <pubDate>Tue, 19 Nov 2024 00:00:00 GMT</pubDate> <description>Retinoblastoma, a rare but aggressive eye cancer in infants and young children, accounts for 2% to 4% of pediatric malignancies globally, with an incidence rate ranging from 1 in 20 000 to 1 in 15 000 children. Approximately 8000 new cases are reported annually across the globe, of which more than 1000 are reported in China. Notably, regions with the highest prevalence, such as Asia and Africa, have the highest mortality rates, ranging from 40% to 70%, in stark contrast with the 3% to 5% mortality rate in high-income countries. According to the definition of rare cancers from the European RARECARE project (&amp;lt;6/100 000 people), retinoblastoma is considered a rare cancer with significant unmet clinical needs owing to the limited information available regarding its diagnosis and treatment. In 2018, the National Health Commission of China announced the “catalog for the first batch of rare diseases”; retinoblastoma appeared in this list, indicating its priority for policymakers in promoting the treatment of retinoblastoma. As a rare cancer, the number of clinical trials conducted for retinoblastoma is limited, particularly in low- and middle-income countries. Most of the existing research originates from high-income countries. However, high-income countries account for less than 10% of the global retinoblastoma cases, while low- and middle-income countries in Asia, Africa, and Latin America represent more than 80% of the cases.</description> <prism:volume xmlns:prism="prism">332</prism:volume> <prism:number xmlns:prism="prism">19</prism:number> <prism:startingPage xmlns:prism="prism">1618</prism:startingPage> <prism:endingPage xmlns:prism="prism">1620</prism:endingPage> <prism:doi xmlns:prism="prism">10.1001/jama.2024.21396</prism:doi> <guid>2825271</guid> </item> <item> <title>Management of Depression</title> <link>https://jamanetwork.com/journals/jama/fullarticle/2825167</link> <pubDate>Tue, 19 Nov 2024 00:00:00 GMT</pubDate> <description>To the Editor The Review by Dr Simon and colleagues on management of depression in adults provides many treatment options for depressive illnesses. However, we were surprised and disappointed that monoamine oxidase inhibitors (MAOIs), a well-established treatment, were not included among the third-line treatment options for nonresponding depression. There are more than 6 decades of data confirming MAOIs’ efficacy in controlled trials and meta-analyses. In addition, MAOIs are included in national and international treatment guidelines and expert reviews for refractory mood disorders.</description> <prism:volume xmlns:prism="prism">332</prism:volume> <prism:number xmlns:prism="prism">19</prism:number> <prism:startingPage xmlns:prism="prism">1673</prism:startingPage> <prism:endingPage xmlns:prism="prism">1673</prism:endingPage> <prism:doi xmlns:prism="prism">10.1001/jama.2024.18393</prism:doi> <guid>2825167</guid> </item> <item> <title>Management of Depression</title> <link>https://jamanetwork.com/journals/jama/fullarticle/2825166</link> <pubDate>Tue, 19 Nov 2024 00:00:00 GMT</pubDate> <description>To the Editor I read the Review on management of depression in adults by Dr Simon and colleagues with great interest. I would like to provide some supplementary information with regard to one of their references, and I would also like to add a cautionary note on their use of the term mild depression.</description> <prism:volume xmlns:prism="prism">332</prism:volume> <prism:number xmlns:prism="prism">19</prism:number> <prism:startingPage xmlns:prism="prism">1674</prism:startingPage> <prism:endingPage xmlns:prism="prism">1674</prism:endingPage> <prism:doi xmlns:prism="prism">10.1001/jama.2024.18396</prism:doi> <guid>2825166</guid> </item> <item> <title>Management of Depression</title> <link>https://jamanetwork.com/journals/jama/fullarticle/2825165</link> <pubDate>Tue, 19 Nov 2024 00:00:00 GMT</pubDate> <description>To the Editor We read with great interest the Review on management of depression by Dr Simon and colleagues. We appreciate the comprehensive view of the patient, the attention paid to nonpharmacological treatment, and the thinking process guiding the choice of antidepressants. However, we could not find trazodone among the antidepressants. Possibly, the search criteria accounted for this gap. Nevertheless, trazodone is a US Food and Drug Administration–approved antidepressant and, at low doses (50-150 mg/d), is also used to treat sleep disorders and anxiety as well as behavioral and psychological symptoms of dementia. Treatment effects occur through a complex central mechanism of action: trazodone increases noradrenaline release and turnover through a 2-presynaptic receptor and is a 5-hydroxytryptamine 2 antagonist and serotonin reuptake inhibitor, with moderate histamine 1 receptor antagonism properties. Trazodone is primarily an antidepressant at dosages up to 300 mg/d. Trazodone has no anticholinergic effects, neither causes nor worsens parkinsonism, and does not affect libido. However, hypotension and dizziness are not uncommon adverse effects. Trazodone serum levels may vary depending upon genetic P-glycoprotein polymorphisms, but trazodone does not affect liver cytochromes and thus does not have many drug interactions. The lack of drug interactions and the high prevalence of sleep problems and anxiety in elderly patients make trazodone a potentially useful antidepressant in geriatric medicine. Thus, we think that a Review on the treatment of depression should include trazodone to provide the readers of JAMA with complete information on the available pharmacological choices.</description> <prism:volume xmlns:prism="prism">332</prism:volume> <prism:number xmlns:prism="prism">19</prism:number> <prism:startingPage xmlns:prism="prism">1673</prism:startingPage> <prism:endingPage xmlns:prism="prism">1674</prism:endingPage> <prism:doi xmlns:prism="prism">10.1001/jama.2024.18399</prism:doi> <guid>2825165</guid> </item> <item> <title>Management of Depression</title> <link>https://jamanetwork.com/journals/jama/fullarticle/2825164</link> <pubDate>Tue, 19 Nov 2024 00:00:00 GMT</pubDate> <description>To the Editor We read with great interest the recent Review by Dr Simon and colleagues on management of depression in adults. Although we commend the authors for their accomplishment in synthesizing large amounts of evidence in this field, we consider the article’s focus on the management of the more severe forms of depression to be insufficient and therefore the title of the article to be somewhat misleading. Specifically, although the authors spend several paragraphs discussing complementary and alternative forms of treatment with small to medium effect sizes, they only briefly mention electroconvulsive therapy (ECT), which they consider a third-line therapeutic option. This is surprising because ECT has been established for decades as the most effective treatment for acute severe depression, with effect sizes compared with medication or sham ECT greater than 0.80 and particularly high remission rates in psychotic depression. Hence, when used prudently and for the right patients, ECT ranks among the most powerful interventions not only in psychiatry, but in all of medicine. It is furthermore superior in efficacy to other interventions mentioned by the authors, such as transcranial magnetic stimulation and ketamine.</description> <prism:volume xmlns:prism="prism">332</prism:volume> <prism:number xmlns:prism="prism">19</prism:number> <prism:startingPage xmlns:prism="prism">1672</prism:startingPage> <prism:endingPage xmlns:prism="prism">1673</prism:endingPage> <prism:doi xmlns:prism="prism">10.1001/jama.2024.18402</prism:doi> <guid>2825164</guid> </item> <item> <title>Management of Depression—Reply</title> <link>https://jamanetwork.com/journals/jama/fullarticle/2825163</link> <pubDate>Tue, 19 Nov 2024 00:00:00 GMT</pubDate> <description>In Reply We thank all correspondents for their attention to our work. Our Review intended to focus on questions most relevant to primary care and other general medical clinicians and gave less attention to questions more relevant to mental health specialty care.</description> <prism:volume xmlns:prism="prism">332</prism:volume> <prism:number xmlns:prism="prism">19</prism:number> <prism:startingPage xmlns:prism="prism">1674</prism:startingPage> <prism:endingPage xmlns:prism="prism">1675</prism:endingPage> <prism:doi xmlns:prism="prism">10.1001/jama.2024.18405</prism:doi> <guid>2825163</guid> </item> <item> <title>Three vs 6 Cycles of Chemotherapy for High-Risk Retinoblastoma</title> <link>https://jamanetwork.com/journals/jama/fullarticle/2825162</link> <pubDate>Tue, 19 Nov 2024 00:00:00 GMT</pubDate> <description>This randomized clinical trial examines whether 3 cycles of carboplatin, etoposide, and vincristine chemotherapy is noninferior to 6 cycles for enucleated unilateral retinoblastoma with high-risk pathological features.</description> <prism:volume xmlns:prism="prism">332</prism:volume> <prism:number xmlns:prism="prism">19</prism:number> <prism:startingPage xmlns:prism="prism">1634</prism:startingPage> <prism:endingPage xmlns:prism="prism">1641</prism:endingPage> <prism:doi xmlns:prism="prism">10.1001/jama.2024.19981</prism:doi> <guid>2825162</guid> </item> <item> <title>Mpox Clinical Presentation, Diagnostic Approaches, and Treatment Strategies</title> <link>https://jamanetwork.com/journals/jama/fullarticle/2825027</link> <pubDate>Tue, 19 Nov 2024 00:00:00 GMT</pubDate> <description>This review examines the epidemiology, transmission, clinical presentation, assessment and diagnosis, prognosis, management and treatment, and prevention of mpox.</description> <prism:volume xmlns:prism="prism">332</prism:volume> <prism:number xmlns:prism="prism">19</prism:number> <prism:startingPage xmlns:prism="prism">1652</prism:startingPage> <prism:endingPage xmlns:prism="prism">1662</prism:endingPage> <prism:doi xmlns:prism="prism">10.1001/jama.2024.21091</prism:doi> <guid>2825027</guid> </item> <item> <title>Risk and Benefit of Restrictive Transfusion Strategies in Neurocritically Ill Patients</title> <link>https://jamanetwork.com/journals/jama/fullarticle/2824932</link> <pubDate>Tue, 19 Nov 2024 00:00:00 GMT</pubDate> <description>Acute neurological injuries, especially traumatic brain injuries and subarachnoid hemorrhages, often affect young and previously healthy patients with years of active life to come. Mortality remains very high following any severe acute brain injury, and importantly, a significant proportion of survivors have long-term sequelae that prevent them from independent living. Despite proliferation of dedicated neurocritical care units and improvements in patient management over past decades, very few interventions clearly improve patient-oriented, clinically significant long-term functional outcomes. Any interventions that could improve functional status in these patients may have a substantial impact.</description> <prism:volume xmlns:prism="prism">332</prism:volume> <prism:number xmlns:prism="prism">19</prism:number> <prism:startingPage xmlns:prism="prism">1615</prism:startingPage> <prism:endingPage xmlns:prism="prism">1617</prism:endingPage> <prism:doi xmlns:prism="prism">10.1001/jama.2024.20416</prism:doi> <guid>2824932</guid> </item> <item> <title>Restrictive vs Liberal Transfusion Strategy in Patients With Acute Brain Injury</title> <link>https://jamanetwork.com/journals/jama/fullarticle/2824930</link> <pubDate>Tue, 19 Nov 2024 00:00:00 GMT</pubDate> <description>This randomized clinical trial assesses the effect of a liberal vs a restrictive hemoglobin threshold for red blood cell transfusion on unfavorable neurological outcome in patients with acute brain injury.</description> <prism:volume xmlns:prism="prism">332</prism:volume> <prism:number xmlns:prism="prism">19</prism:number> <prism:startingPage xmlns:prism="prism">1623</prism:startingPage> <prism:endingPage xmlns:prism="prism">1633</prism:endingPage> <prism:doi xmlns:prism="prism">10.1001/jama.2024.20424</prism:doi> <guid>2824930</guid> </item> <item> <title>Regulations for Implementing Virtual Care Technology for Patients With Disabilities</title> <link>https://jamanetwork.com/journals/jama/fullarticle/2824831</link> <pubDate>Tue, 19 Nov 2024 00:00:00 GMT</pubDate> <description>This Viewpoint discusses the new federal regulations that require health care institutions to develop virtual care technologies that are accessible to patients with disabilities.</description> <prism:volume xmlns:prism="prism">332</prism:volume> <prism:number xmlns:prism="prism">19</prism:number> <prism:startingPage xmlns:prism="prism">1611</prism:startingPage> <prism:endingPage xmlns:prism="prism">1612</prism:endingPage> <prism:doi xmlns:prism="prism">10.1001/jama.2024.16528</prism:doi> <guid>2824831</guid> </item> <item> <title>Decline of Mpox Antibody Responses After Modified Vaccinia Ankara–Bavarian Nordic Vaccination</title> <link>https://jamanetwork.com/journals/jama/fullarticle/2824688</link> <pubDate>Tue, 19 Nov 2024 00:00:00 GMT</pubDate> <description>This study assesses mpox-specific immune responses for 12 months after MVA-BN vaccination.</description> <prism:volume xmlns:prism="prism">332</prism:volume> <prism:number xmlns:prism="prism">19</prism:number> <prism:startingPage xmlns:prism="prism">1669</prism:startingPage> <prism:endingPage xmlns:prism="prism">1672</prism:endingPage> <prism:doi xmlns:prism="prism">10.1001/jama.2024.20951</prism:doi> <guid>2824688</guid> </item> <item> <title>Fecal Immunochemical Test and Helicobacter pylori Stool Antigen Co-Testing</title> <link>https://jamanetwork.com/journals/jama/fullarticle/2824280</link> <pubDate>Tue, 19 Nov 2024 00:00:00 GMT</pubDate> <description>Gastric cancer is a leading cause of cancer death globally. Although endoscopy-based screening has led to a decrease in gastric cancer mortality in Eastern Asian countries with populations at high risk, lack of risk stratification and the cost of health care infrastructure and trained personnel limit its use in most of the world. Availability of noninvasive biomarkers for the identification of high-risk individuals could optimize endoscopy-based screening programs for a more general application, including in regions where gastric cancer rates in the general population are low.</description> <prism:volume xmlns:prism="prism">332</prism:volume> <prism:number xmlns:prism="prism">19</prism:number> <prism:startingPage xmlns:prism="prism">1621</prism:startingPage> <prism:endingPage xmlns:prism="prism">1622</prism:endingPage> <prism:doi xmlns:prism="prism">10.1001/jama.2024.8611</prism:doi> <guid>2824280</guid> </item> <item> <title>Screening for Helicobacter pylori to Prevent Gastric Cancer</title> <link>https://jamanetwork.com/journals/jama/fullarticle/2824276</link> <pubDate>Tue, 19 Nov 2024 00:00:00 GMT</pubDate> <description>This randomized clinical trial evaluates the effects of Helicobacter pylori stool antigen assessment plus fecal immunochemical testing (FIT), vs FIT alone, on gastric cancer incidence and mortality among adults in Taiwan.</description> <prism:volume xmlns:prism="prism">332</prism:volume> <prism:number xmlns:prism="prism">19</prism:number> <prism:startingPage xmlns:prism="prism">1642</prism:startingPage> <prism:endingPage xmlns:prism="prism">1651</prism:endingPage> <prism:doi xmlns:prism="prism">10.1001/jama.2024.14887</prism:doi> <guid>2824276</guid> </item> <item> <title>Preventive Care Coverage Threatened by Federal Court Ruling</title> <link>https://jamanetwork.com/journals/jama/fullarticle/2823961</link> <pubDate>Tue, 19 Nov 2024 00:00:00 GMT</pubDate> <description>This Viewpoint highlights the 2 most concerning aspects of the Braidwood Management Inc v Becerra ruling and their potential effect on health equity.</description> <prism:volume xmlns:prism="prism">332</prism:volume> <prism:number xmlns:prism="prism">19</prism:number> <prism:startingPage xmlns:prism="prism">1605</prism:startingPage> <prism:endingPage xmlns:prism="prism">1606</prism:endingPage> <prism:doi xmlns:prism="prism">10.1001/jama.2024.16439</prism:doi> <guid>2823961</guid> </item> <item> <title>The US Preventive Services Task Force in Legal Jeopardy</title> <link>https://jamanetwork.com/journals/jama/fullarticle/2823960</link> <pubDate>Tue, 19 Nov 2024 00:00:00 GMT</pubDate> <description>This work discusses the Braidwood Management Inc v Becerra case and how the intent of Congress, the health of the public, and the law may come into conflict.</description> <prism:volume xmlns:prism="prism">332</prism:volume> <prism:number xmlns:prism="prism">19</prism:number> <prism:startingPage xmlns:prism="prism">1607</prism:startingPage> <prism:endingPage xmlns:prism="prism">1608</prism:endingPage> <prism:doi xmlns:prism="prism">10.1001/jama.2024.17377</prism:doi> <guid>2823960</guid> </item> <item> <title>H5 Influenza Vaccines</title> <link>https://jamanetwork.com/journals/jama/fullarticle/2823004</link> <pubDate>Tue, 19 Nov 2024 00:00:00 GMT</pubDate> <description>This Viewpoint discusses H5 influenza vaccine use in light of the current outbreak and how vaccine development, stockpiling, and deployment could shape the US’ response to future pandemics.</description> <prism:volume xmlns:prism="prism">332</prism:volume> <prism:number xmlns:prism="prism">19</prism:number> <prism:startingPage xmlns:prism="prism">1609</prism:startingPage> <prism:endingPage xmlns:prism="prism">1610</prism:endingPage> <prism:doi xmlns:prism="prism">10.1001/jama.2024.17488</prism:doi> <guid>2823004</guid> </item> </channel> </rss>